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siRNA Knockdown of Ribonucleotide Reductase
Inhibits Melanoma Cell Line Proliferation Alone or
Synergistically with Temozolomide
Jonathan E. Zuckerman1,2, Teli Hsueh1, Richard C. Koya3, Mark E. Davis2 and Antoni Ribas1,3,4
Systemically delivered small interfering RNA (siRNA) therapies for cancer have begun clinical development. The
effects of siRNA-mediated knockdown of ribonucleotide reductase subunit-2 (RRM2), a rate-limiting enzyme in
cell replication, were investigated in malignant melanoma, a cancer with a paucity of effective treatment
options. A panel of human melanoma cell lines was transfected with siRNA to induce the knockdown of RRM2.
Sequence-specific, siRNA-mediated inhibition of RRM2 effectively blocked cell proliferation and induced
G1/S-phase cell cycle arrest. This effect was independent of the activating oncogenic mutations in the tested cell
lines. Synergistic inhibition of melanoma cell proliferation was achieved using the combination of siRNA
targeting RRM2 and temozolomide, an analog of the current standard of care for melanoma chemotherapy. In
conclusion, siRNA-mediated RRM2 knockdown significantly inhibits proliferation of melanoma cell lines with
different oncogenic mutations with synergistic enhancement in combination with temozolomide.
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INTRODUCTION
The incidence of malignant melanoma is rising faster than
any other cancer. The treatment outcomes of metastatic
melanoma remain dismal (Tsao et al., 2004; Miller and
Mihm, 2006). Only 10–15% of patients with disseminated
disease respond to standard of care therapy with dacarbazine
(DTIC) (Augustine et al., 2009). Temozolomide is a second-
generation alkylating agent, in which active metabolite
5-(3-methyltriazen-1-yl)imidazole-4-carboximide has a me-
chanism of action analogous to DTIC, with the added benefit
of crossing the blood–brain barrier, an important feature as
metastatic melanoma frequently metastasizes to the brain
(Tsao et al., 2004; Augustine et al., 2009).
The first experimental therapeutic to provide targeted
delivery of synthetic, small interfering RNA (siRNA) in
humans, CALAA-01, is currently being tested in a phase 1
clinical trial (Davis, 2009). This targeted, nanoparticle
formulation of siRNA consists of a cyclodextrin-containing
polymer (CDP) utilizing human transferrin as a targeting
ligand for binding to transferrin receptors that are typically
upregulated on cancer cells. The siRNA component of
CALAA-01, called siR2Bþ5, was designed to target ribo-
nucleotide reductase subunit-2 (RRM2) and had been
characterized for potency, efficacy, and specificity (Heidel
et al., 2007a; Davis, 2009).
Ribonucleotide reductase (RR) catalyzes the rate-limiting
step in the production of 20-deoxyribonucleoside 50-tripho-
sphates needed for DNA replication. Conversion of ribonu-
cleoside 50-diphosphates to 20deoxyribonucleotides by
human RR requires expression of both its subunits, RRM1
and RRM2 (Engstrom et al., 1985). The subunits are
differentially expressed during the cell cycle. Whereas
RRM1 expression remains constant throughout the cell cycle,
the RRM2 subunit is only expressed in the late G1/early
S-phase of the cell cycle (Engstrom et al., 1985). RRM2 is
therefore an attractive therapeutic target as it is primarily
expressed in proliferating cells, such as cancer cells.
RRM2 has been a validated target for cancer therapy.
Several small molecule agents such as hydroxyurea, alkoxy-
phenols, and cytarabine inhibit RRM2 activity; however, they
are also associated with dose-limiting toxicities due to
adverse effects on non-malignant cells, e.g., bone marrow
suppression (Shao et al., 2006). Antisense RNA-based
therapeutics targeting RRM2 have also shown some promise
in the clinic, but are also associated with severe dose-limiting
toxicities (hepatotoxicity) and the need to be administered via
continuous infusion (Desai et al., 2005). Cancer therapy
using targeted nanoparticles formulated with siRNA targeting
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RRM2 may be able to bypass some of the undesirable
nonspecific effects caused by traditional small molecule-
based therapeutics, as the specific targeting properties of the
nanoparticle systems allow for a more selective delivery to
tumor tissue (Davis, 2009). CALAA-01-like-nanoparticles
have been shown to have very little nonspecific toxicity.
Importantly, no hematopoietic toxicity was observed after
administration of high doses to cynomolgus monkeys (Heidel
et al., 2007b).
CALAA-01 has been administered to 15 patients with solid
refractory cancers within an open-label, dose-escalation trial.
Biopsies in two patients with metastatic melanoma demon-
strated tumor targeting with the presence of particles within
tumors (Davis et al., 2010). At the highest dose tested
(30mgm2), there was evidence of RRM2 knockdown when
analyzed both at the mRNA and protein levels. Furthermore,
specific confirmation of triggering the RNA interfering (RNAi)
mechanism was obtained by the demonstration of the
presence of the specific cleavage sequence of siRNA
targeting RRM2 in tumor samples by 50-RNA ligand-mediated
rapid amplification of complementary DNA ends (50-RLM-
RACE) PCR technique (Davis et al., 2010).
The evidence of RRM2 silencing in vivo with CALAA-01
provided motivation to study the mechanism and range of
effects of siR2Bþ5 siRNA-induced RRM2 knockdown
in vitro against a previously characterized panel of melanoma
cell lines (Søndergaard et al., 2010). Therefore, in this study
we sought to elucidate the efficacy of siR2Bþ5 siRNA-
induced RRM2 knockdown to inhibit melanoma cell
proliferation, to determine the mechanism of antiproliferative
effects, and to identify the range of sensitivities of different
melanoma cell lines with defined oncogenic alterations to
this new therapeutic approach, which may indicate patient
populations that may most benefit from this therapeutic
approach. Additionally, synergy studies involving siR2Bþ 5
siRNA and temozolomide were carried out.
RESULTS
RRM2 silencing in HT-144 melanoma cells by siR2Bþ 5 siRNA
via RNAi mechanism
We first demonstrated that the siR2Bþ 5 siRNA sequence
previously characterized by Heidel et al. (2007a) successfully
knocked down RRM2 expression in melanoma cells. We
transfected HT-144 cells with either 5 nmol l1 siR2Bþ 5
siRNA or a non-targeting control (siCON) siRNA and
measured the RRM2 mRNA and protein expression by
quantitative real-time reverse transcription PCR and western
blot, respectively (Figure 1a and b). We observed
480% reduction in RRM2 mRNA and 90% RRM2 protein
knockdown following siR2Bþ 5 treatment when compared
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Figure 1. Knockdown of ribonucleotide reductase subunit-2 (RRM2) mRNA and protein expression by small interfering RNA (siRNA) siR2Bþ 5 in melanoma
cells. (a) Quantitative real-time reverse transcription PCR analysis of RRM2 mRNA levels in HT-144 cells 48 hours after transfection with 5 nmol l1 of RRM2-
targeted siRNA (siR2Bþ 5) or a non-targeting control (siCON) siRNA (error bars, n¼3). (b) Quantification of RRM2 protein expression by western blot band
densitometry analysis, average of three independent experiments; one blot is pictured (error bars, n¼3). 50-RNA ligand-mediated rapid amplification of
complementary DNA ends detection of siRNA induced mRNA cleavage fragment HT-144 cells transfected using either (c) LipofectamineRNAiMax or (d)
targeted cyclodextrin-containing polymer (CDP)/siRNA nanoparticles (arrows point to position of the predicted 209 bp amplicon). (e) Sequencing
chromatographs from positive rapid amplification of complementary DNA end bands.
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with siCON treatment (Figure 1a and b). We were able to
obtain similar levels of RRM2 protein knockdown (60–90%)
with siR2Bþ5 treatments in all other cell lines tested for
RRM2 expression (data not shown).
In order to confirm that siR2Bþ5 does in fact engage the
canonical RNAi machinery, RNA from HT-144 cells
transfected with siR2Bþ5 and siCON using Lipofectami-
neRNAiMax or targeted CPD/siRNA nanoparticles (similar
to CALAA-01) were subjected to 50-RLM-RACE analysis
(Figure 1c and d). RRM2 mRNA fragments, whose 50 ends
matched the predicted siRNA-induced cleavage site (10 base
pairs from the 50 end of the antisense strand) were detected
only in those samples treated with the siR2Bþ 5 siRNA using
either LipofectamineRNAiMax or targeted CDP/siRNA nano-
particles (Figure 1c–e). LipofectamineRNAiMax was used for
all subsequent transfections as it has much higher transfeciton
efficiency than the targeted CDP/siRNA nanoparticles in vitro
(data not shown). Several nonspecific bands were also
observed in the siCON-treated samples; however, none of
these bands matched the size or sequence of the correct
RACE product obtained in the siR2Bþ5 samples.
siR2Bþ 5 treatment inhibits cell proliferation in a panel of
melanoma cell lines in vitro
We hypothesize that RRM2 is required for melanoma cell
proliferation and knockdown of its expression in melanoma
cell lines would result in growth inhibition. In order to test
this hypothesis, 13 human melanoma cell lines with previous
detailed oncogenic characterization (Søndergaard et al.,
2010) as well as 3 non-melanoma cell lines (2 breast cancer:
MDA-MB-231 and MCF-7 and a normal fibroblast cell line
3T3) were treated with either 5 nmol l1 siR2Bþ 5 or siCON
siRNA and their viability levels compared to untreated
control samples (Figure 2a). We observed up to 20%
nonspecific decrease in cell viability following treatment
with the negative control siCON siRNA. Therefore, we
considered that a cell line was sensitive to siR2Bþ5 siRNA
treatment if cell viability was o80% of the untreated control
following siR2Bþ 5 siRNA treatment (dashed line). We found
that 10 out of the 13 cell lines tested were sensitive to
siR2Bþ5 siRNA treatment. Among those sensitive cell lines,
we observed a wide range of siR2Bþ 5 siRNA-induced
proliferation inhibition, with the most sensitive cell lines
(e.g., PTM, M238) demonstrating an B65% decrease in
viability following treatment, whereas the least sensitive cell
lines (e.g., M207, M229) demonstrate B30% decrease in
viability. It is notable that two out of the three cell lines
(M243, M245), which did not show antiproliferative effects
after siR2Bþ5 siRNA treatment at 72 hours, ultimately
showed decreased proliferation at later time points (data
not shown). Melanoma has frequent activating mutations in
the mitogen-activated protein pathway, with mutually
exclusive activating mutations in NRAS and BRAF (Gray-
Schopfer et al., 2007). However, the differences in sensitivity
appear to be independent of the activated oncogene present
in each cell, as antiproliferative effects were equivalent in
cell lines that had been previously characterized as having
NRASQ61L or BRAFV600E activating mutations (Søndergaard
et al., 2010). As expected siR2Bþ 5 treatment in 3T3 cells
lead to significant decrease in cell viability. Surprisingly, we
observed no antiproliferative effects of RRM2 knockdown
in the two human breast cancer cell lines tested at 72 hours.
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Figure 2. In vitro antiproliferative effects of ribonucleotide reductase subunit-2 knockdown by siR2Bþ 5 small interfering RNA (siRNA) in a panel of
melanoma cell lines. (a) Bioluminescent-based viability assay on a panel of cell lines 72 hours after transfection with 5 nmol l1 siRNAs, siR2Bþ5 (black
columns), or siCON (white columns). Cell line oncogenic mutations are indicated by (*) NRAS codon 61 mutation, (þ ) BRAF V600E mutation, or (z) NRAS/
BRAF wild type. (b) MTS viability assay of M202 melanoma cells transfected with a range of siR2Bþ 5 concentrations from 0.005 to 50 nmol l1 (black circles),
or siCON 0.5–50 nmol l1 (white circles) performed at 48, 72, 96, and 120 hours following transfection (only the 120-hour siCON time points are displayed). All
cell viability data are normalized to untreated control samples (error bars, n¼3).
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The MDA-MB-231 cell line, but not MCF-7 cell line,
does show decreased proliferation at later time point (data
not shown).
The dose and time dependence of siR2Bþ5 siRNA was
investigated in order to better understand the amount of
siR2Bþ5 siRNA necessary to induce sustained antiprolifera-
tive effects. We transfected M202 cells with a range of
siR2Bþ5 siRNA concentrations (0.005–50 nmol l1) and
measured cell viability at 48, 72, 96, and 120hours after
transfection (Figure 2b). We observed a clear dose- and time-
dependent sensitivity to siR2Bþ 5 siRNA. Antiproliferative
effects at o0.1 nmol l1 siR2Bþ5 siRNA were observed and
reached a plateau at 3 nmol l1. We observed increasing
antiproliferative effects with each time point up to 120 hours,
at which these effects stabilized. We also observed some
amount of dose-dependent toxicity after siCON treatment,
with levels about 10 nmol l1 showing significant decrease in
cell viability; however, these effects were not time dependent
and did not change significantly from 48 to 120 hours (only
120 hours data pictured).
siR2Bþ 5 treatment induced G1/S-phase cell cycle arrest in
multiple cell lines
We hypothesize that RRM2 knockdown depletes the pool of
available dNTPs for DNA synthesis. Therefore, cells treated
with siR2Bþ5 siRNA should not be able to replicate their
genomes and arrest early in the cell cycle. These molecular
events may lead to the observed antiproliferative effects after
RRM2 knockdown. In order to test this hypothesis, we
analyzed the cell cycle distribution of HT-144 melanoma
cells, a cell line sensitive to siR2Bþ5 siRNA treatment, using
propidium iodide staining after treatment with either
5 nmol l1 siR2Bþ5 or siCON siRNA (Figure 3a). Significant
changes to cell cycle distribution in siR2Bþ5 siRNA-treated
cells compared with siCON siRNA-treated samples were
observed. Compared with siCON siRNA-treated samples,
siR2Bþ5 siRNA-treated samples had a marked increase in
G1- and S-phase populations, and near disappearance of the
G2/M-phase population, consistent with G1/S-phase cell
cycle arrest.
We analyzed whether RRM2 knockdown after siR2Bþ 5
treatment leads to apoptosis in addition to cell cycle arrest. In
order to examine for this possibility, we stained siR2Bþ5
siRNA-treated HT-144 cells with annexin-V-FITC and propi-
dium iodide to identify live, apoptotic, and dead cellular
populations by flow cytometry (Figure 3b). Untreated
samples had a baseline population made up ofB7% of cells
with spontaneous apoptotsis detected as Annexin-V-positive
cells, with or without being propidium iodine positive
(Figure 3b). Treatment with 2.5 or 5 nmol l1 siCON siRNA
caused an increase in this population over 10%. Samples
treated with 2.5 or 5 nmol l1 siR2Bþ5 siRNA demonstrated
an additional 3–5% increase in apoptotic cell populations.
There were minimal non-apoptotic dead cells in any
sample. Overall, siR2Bþ 5 siRNA treatment, compared
with untreated and siCON siRNA-treated samples, resulted
in marked cell cycle arrest, but only a marginal increase in
apoptotic cell death at the conditions and timing tested by us.
We further hypothesized that the differences in sensitivity
among cell lines to siR2Bþ 5 siRNA in terms of growth
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Figure 3. G1/S-phase cell cycle arrest, but little apoptosis, is induced by siR2Bþ 5 small interfering RNA ribonucleotide reductase subunit-2 knockdown.
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inhibition may be based upon the completeness of cell cycle
arrest achieved after RRM2 knockdown in each cell line. We
compared cell cycle analysis profiles of M202 (a good
responder by cell viability assays) and M207 (a cell line with
minimal response) after treatment with siR2Bþ 5 or siCON
siRNA (Figure 4a and b). As shown above, M202 cell
proliferation is greatly inhibited after RRM2 knockdown,
whereas M207 cell proliferation is more weakly inhibited.
Inspection of the cell cycle analysis data for both cell lines
after treatment with siR2Bþ 5 siRNA demonstrate enrich-
ment of G1-phase cell populations and diminishment of S-
phase populations in both cell lines; however, the G2/M-
phase population of M202 cells nearly disappears after RRM2
knockdown, whereas this population of M207 cells only
decreases by half, suggesting that some M207 cells were still
cycling, despite a similar level of RRM2 knockdown (Figure
4c and d).
Combination of temozolomide and RRM2 knockdown is
synergistic for inhibition of cell proliferation
We tested if RRM2 knockdown in melanoma cell lines may
sensitize melanoma cells to temozolomide treatment, which
is an agent frequently used as standard of care in the
treatment of patients with metastatic melanoma. Given the
relatively high concentrations required of temozolomide (and
DMSO vehicle control) for these experiments, we solubilized
temozolomide using a solution of 2-hydroxypropyl-b-cyclo-
dextrin, in order to avoid any confounding of results due to
toxicities from high concentrations of DMSO. We did not
observe any cytotoxic effects of 2-hydroxypropyl-b-cyclo-
dextrinalone in our cell lines (data not shown). The initial
studies focused on lower doses of temozolomide; however,
no cytotoxic effects were observed for temozolomide alone at
these doses. Additionally, no additional antiproliferative
activity was observed following temozolomide addition to
siR2Bþ5 siRNA treatment at these low doses (data not
shown). Therefore, we increased the dose of temozolomide
to a range, at which a cytotoxic effect of temozolomide alone
could be observed.
In these high concentration synergy studies, M202 or HT-
144 melanoma cell lines were treated with increasing doses
of siR2Bþ5 (0–20.2 nmol l1) followed by temozolomide
treatment (24 hours later), with viability readings taken
48 hours after the temozolomide treatment (Figure 5a
and b). Samples treated with only temozolomide demon-
strated minimal decrease in viability except at the highest
dose. siR2Bþ 5 siRNA treatment produced similarly potent
antiproliferative effects as observed in previous experiments.
The combination of temozolomide and siR2Bþ5 siRNA
produced antiproliferative effects greater than either indivi-
dual agent alone. Synergy was determined by combination
index (CI) methods, based on Chou-Talalay equations
(Figure 5c and d). We observed that all combination doses
in M202 cells showed synergistic effects, with CIso1, and all
but the lowest dose of the combination therapy in HT-144
cells demonstrating synergistic effects.
DISCUSSION
In this report, we demonstrate the therapeutic potential of
siRNA targeting RRM2 in melanoma cell lines. siR2Bþ 5
siRNA efficiently knocks down RRM2 expression by the
canonical RNAi mechanism in melanoma cell lines and leads
to a significant decrease in proliferative capacity in the
majority of melanoma cell lines tested. Moreover, we
demonstrate, by 50-RLM-RACE, that siRNA delivered by
targeted CDP/siRNA nanoparticles can engage the RNAi
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machinery in vitro. Additionally, we find that the therapeutic
response was durable, lasting for more than 120 hours post-
transfection, and potent, demonstrated by therapeutic doses
o1 nmol l1.
These results are consistent with previous data obtained by
Heidel et al. (2007a) that demonstrated siR2Bþ5 siRNA
induced growth inhibition of a variety of cancer cell lines
in vitro and in vivo. (Avolio et al. (2007) have also reported
that siRNA targeting RRM2 decreased tumor growth rates
in vivo Lee et al. (2003) demonstrated that targeting RR using
antisense RNA molecules can inhibit proliferation of mela-
noma cell lines in vitro and in vivo. Additionally, these
authors showed significant inhibition of lung tumor colonies
following tail vein injections of A2508 melanoma cells into
mice after 5–7 weeks of daily treatment with GTI-2040, a
20-nucleotide phosphorothioate oligodeoxyribunucleotide
that has been reported to inhibit the production of RRM2
in vitro (Lee et al., 2003).
Intriguingly, several reports, most notably from Duxbury
et al. (2004), demonstrated that RRM2 knockdown alone in
certain cancer models (pancreatic adenocarcinoma cell lines)
did not decrease cell viability. However, Reid et al. (2009)
have demonstrated that RRM2 knockdown in A549 melano-
ma cell lines inhibits growth in vitro and in vivo. The variety
of responses to RRM2 knockdown among melanoma cell
lines used here emphasizes the importance of screening a
panel of cancer cell lines when evaluating siRNA therapeu-
tics. Additionally, the lack of any robust antiproliferative
effect in the breast cancer cell lines tested suggests that
melanoma, in general, may be more sensitive to siR2Bþ 5
therapy than other cancer types.
Our data suggest that growth inhibition following
siR2Bþ5 siRNA treatment is due mostly to G1/S-phase cell
cycle arrest, with some limited contribution from apoptotic
events. Cell cycle arrest following RRM2 knockdown has
been observed in renal cell carcinoma cell lines; however,
unlike the melanoma cell lines in this report, RRM2 knock-
down caused S-phase arrest with no particular enrichment of
the G1-phase population of cells (Avolio et al., 2007).
Conversely, in colon cancer cell lines, no perturbations to the
cell cycle were observed following RRM2 knockdown
(Lin et al., 2004).
We observed a limited amount of apoptosis in HT-144
melanoma cells following RRM2 knockdown. However, the
increase in apoptotic population in siR2Bþ 5 siRNA-treated
cells compared with those treated with siCON siRNA is not of
sufficient magnitude to explain the large difference in growth
inhibition observed between HT-144 cells treated with
siR2Bþ5 and siCON siRNA. Therefore, it is likely that
RRM2 knockdown with siR2Bþ5 siRNA primarily has
cytostatic effects, as opposed to cytotoxic cell killing, in
melanoma cell lines. It is also possible that continuous siRNA
treatment for long periods of time in vivo through repeated
dosing with targeted nanoparticles may lead to eventual
melanoma cell death. However, the conditions for continued
exposure to siR2Bþ 5 siRNA are difficult to test experimen-
tally in vitro due to the toxicity of repeated exposure to the
transfection reagents.
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siR2Bþ5 siRNA and temozolomide using the combination index (CI) method. CI values o1 indicate synergy.
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We found that the magnitude of growth inhibition
following siR2Bþ5 siRNA treatment correlated with the
completeness of the observed cell cycle arrest. We found that
in two similar melanoma cell lines, both with activating
N-RasQ61L mutations (M202 and M207 cell lines), siR2Bþ5
siRNA treatment caused varying levels of cell cycle arrest
despite comparable levels of RRM2 knockdown. We
observed complete cell cycle arrest in the M202 cell line
and partial arrest in the M207 cell line. Correspondingly,
M202 cell proliferation was more strongly inhibited by RRM2
knockdown than the proliferation of M207 cells.
Temozolomide at high concentrations has been demon-
strated to induce G2-cell cycle arrest, but not apoptosis, in
melanoma cell lines in vitro (Mhaidat et al., 2007). However,
at more ‘‘clinically relevant’’ concentrations no appreciable
effect on cell cycle, proliferation, or temozolomide-induced
DNA damage has been observed following temozolomide
treatment in human melanoma cell lines (Chen et al., 2009),
which may not be surprising as this agent has a low response
rate in the clinic (Rietschel et al., 2008). Several studies have
suggested that methyl-guanine methyl transferase and RR
may be involved in the temozolomide-resistance mechanism
in cancer (Aghi et al., 2006; Augustine et al., 2009). Our
results suggest that RR may have a role in temozolomide
resistance. We observed that co-treatment with siR2Bþ5
siRNA and temozolomide synergistically inhibited melanoma
cell growth. Therefore, there may be an advantage to
combination therapy with siR2Bþ5 and temozolomide and
further in vivo studies are warranted to fully elucidate the
therapeutic potential of this combination.
MATERIALS AND METHODS
Cell lines and culture
Melanoma cell lines, M202, M207, M229, M233, M238, M245,
M249, M255, M257, and M263, were established from patients’
biopsies under UCLA IRB approval #02-08-067 and have been
previously characterized (Søndergaard et al., 2010). PTM was
provided by Bijay Mukherji (University of Connecticut, Farmington,
CN). The HT-144, MDA-MB-231, MCF-7, and 3T3 cell lines were
obtained from American Type Culture Collection (ATCC, Rockville,
MD). All cell lines were cultured in complete serum media containing
RPMI 160 with L-glutamine (Mediatech, Manassas, VA) with 10% (all
percentages represent v/v) fetal bovine serum (Omega Scientific,
Tarzana, CA), 1% penicillin, streptomycin, and amphotericin (Omega
Scientific) at 37 1C with 5% CO2 in filter-top flasks.
siRNAs duplexes
Both unmodified RNA duplexes were gifts from Calando Pharma-
ceuticals (Pasadena, CA). siCON was bioinformatically designed to
minimize potential for targeting any human gene (Dharmacon,
Lafayette, CO).
siR2Bþ 5: 50-GAUUUAGCCAAGAAGUUCAGA-30
siCON: 50-UAGCGACUAAACACAUCAAUU-30
In vitro transfection
A reverse transfection protocol was followed for siRNA delivery.
siRNA was complexed with LipofectamineRNAiMax (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions. A
quantity of 0.030300nmol l1 siRNA with 0.2% LipofectamineR-
NAiMax was applied to each well in a total volume of 20 ml (96-well
plate) or 500 ml (6-well plate) of Opti-MEM (Invitrogen). In all,
5 103 cells per well (96-well plates) or 2.4 105 (6-well plates)
were plated into wells containing the siRNA formulations, for a final
siRNA concentration of 0.005–50 nmol l1. Targeted CDP/siRNA
nanoparticle delivery of siR2Bþ 5 was performed as described
elsewhere (Bartlett and Davis, 2007) at a final concentration of
300 nmol l1 siRNA.
Temozolomide preparation
Temozolomide (10mgml1) was prepared by dissolving 0.5 g of
temozolomide (LKT Laboratories, St Paul, MN) into 30% (w/v) of
2-hydroxypropyl-b-cyclodextrin (Sigma-Aldrich, St Louis, MO),
at 37 1C in a water bath by stirring at 800 r.p.m. for 60minutes.
Cell viability assays
Cells were transfected as described above and cell viability was
determined using the CellTiterGlo Assay (Promega, Madison, WI) by
following the manufacturer’s instructions. Luminescence was measured
on a DTX 880 multimode detector (Beckman Coulter, Fullerton, CA).
Quantitative real-time reverse transcription PCR
Total RNA from HT-144 cells was extracted using the RNeasy kit
(Qiagen, Valencia, CA). Total RNA samples were reversed tran-
scribed using SuperScriptIII reverse transcriptase. Two ml of prepared
sample complementary DNA was used for triplicate real-time PCR as
described elsewhere (Juhasz et al., 2006). RRM2 levels were
normalized to glyceraldehyde-3-phosphate dehydrogenase levels
within the same sample.
Detection of hRRM2 protein levels by western blot
After 48hours transfection, cells were lysed in RIPA Buffer (Thermo
Fisher Scientific, Waltham, MA). Lysates were diluted to equivalent
protein concentration in b-mercaptoethanol-containing Laimmli
sample buffer (Thermo Fisher Scientific) and incubated at 95 1C
for 5minutes. Antibodies: goat polyclonal anti-R2 antibody, horse-
radish peroxidase-conjugated donkey anti-goat immunoglobulin G
(sc-10846; Santa Cruz Biotechnology, Santa Cruz, CA). Development
was done using SuperSignal West Dura Extended Duration Substrate
(Thermo Fisher Scientific). Band quantification was done using Image-
Quant TL software (GE/Amersham Biosciences, Piscataway, NJ).
hRRM2 expression was normalized to either actin (BD Biosciences,
San Jose, CA) or SID1B, a high-molecular-weight putative RNA
transport protein, using a SID1B antibody (GeneScript, Piscataway, NJ).
50-RLM-RACE
50-RLM-RACE was performed as described previously (Davis et al.,
2010). Briefly, 3 mg or total RNA was ligated directly to 250 ng
GeneRacer RNA adapotor (Invitrogen) using T4 RNA ligase. Ligation
products were reverse transcribed using SuperScriptIII (Invitrogen)
and a RRM2 gene-specific reverse transcription primer. Two rounds
of PCR were performed using a Bio-Rad (Hercules, CA) MJ Mini
personal thermocycler and PCR conditions described previously
(Davis et al., 2010). PCR products were run on a 2% agarose gel and
stained with 1 mg ml1 ethidium bromide. PCR products were excised
from gel and sequenced directly to confirm RACE band identities.
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Cell cycle analysis
Cells were trypsinized and washed twice with phosphate-buffered
saline. Ice cold 70% ethanol was added dropwise while vortexing
and allowed to incubate at 4 1C for 30minutes. Samples were then
centrifuged at 1,300 r.p.m. for 10minutes and the ethanol decanted.
The samples were then stained with 5mgml1 propidium iodide at
room temperature for 30minutes. Cells were then analyzed by flow
cytometery on a FACScan (BD Biosciences) flow cytometer and data
analyzed using FlowJo version 8.7 (Tree Star, Ashland, OR).
Apoptosis analysis
Individual cell culture supernatants were collected. The remaining
adherent cells were trypsinized and combined with the previously
collected supernatant. The samples were then washed with
phosphate-buffered saline and resuspended in 50 ml binding buffer
(BD Biosciences). Samples were treated with 20ml of annexin-V-
FITC at 4 1C for 30minutes. A quantity of 400ml of additional
binding buffer was then added. Five ml of propidium iodide was
added 2minutes before cells were analyzed by flow cytometery on a
FACSCalibur (BD Biosciences). Data analysis was performed using
FACS Express (De Novo Software, Los Angeles, CA).
Combination studies and synergy data analysis
HT-144 cells were transfected with a range of siR2Bþ 5 siRNA
concentrations and incubated for 24hours. Samples were then treated
with a dose range (0–2.636mmol l1) of temozolomide solution
(cyclodextrin concentration was held constant over all samples) in
fresh culture media and were incubated for 72hours and cell viability
assays performed. Analysis of combined agent effects were deter-
mined by CI methods, based on Chou-Talalay equations (Chou, 2006)
using Calcusyn dose effect analyzer software (Biosoft, Cambridge,
UK). This software analysis takes into account the potency of each
individual agent and the combination thereof, as well as the shape of
the each dose–response curve to determine how much the observed
response of the combination treatment differs from the predicted
additive response of the each individual agent. CI values can then be
generated for each dose level, which indicate additive effects (CI¼ 1),
antagonistic effects (CI41), or synergistic effects (CIo1).
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